NEW YORK (GenomeWeb) – With its acquisition this week of Seattle-based Integrated Diagnostics, Biodesix has positioned itself to bring to market one of the first molecular tests to aid identification of early-stage lung cancers, with aims at solving the commercialization puzzle Indi had faced after expending its own resources in development and validation of the test.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.